Microglial in neurodegenerative disorders: emphasis on Alzheimer's disease

Related Experiment Video

Updated: Nov 1, 2026

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques
10:52

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques

Published on: June 1, 2016

A McRae1, A Dahlström, E A Ling

  • 1Institute of Anatomy and Cell Biology, University of Göteborg, Sweden.

Gerontology
|January 1, 1997
PubMed

Insights

Alzheimer's disease (AD) involves immune system changes, with microglia antibodies in cerebrospinal fluid potentially aiding diagnosis. Targeting these immune responses may offer new therapeutic strategies for AD.

Area of Science:

  • Neuroimmunology
  • Pathophysiology of Alzheimer's disease

Background:

  • Alzheimer's disease (AD) hallmark lesions contain reactive microglia, indicating a role for immune system aberrations.
  • Immune-mediated processes may be closely linked to neurodegeneration in AD.
  • A reliable method to detect these immune processes is crucial for understanding AD.

Purpose of the Study:

  • To explore cerebrospinal fluid (CSF) microglial antibodies as potential diagnostic markers for AD.
  • To review the role of neuroinflammation in Alzheimer's disease pathogenesis.
  • To discuss potential therapeutic strategies targeting microglial activity in AD.

Main Methods:

  • Review of current literature on microglial antibodies in CSF.
  • Analysis of antibody recognition in developing rat brain, neuronal cultures, and AD cortical biopsies.
  • Discussion of immunomodulatory treatments for AD.

Main Results:

  • Microglial antibodies are predominantly found in CSF of AD patients.
  • These antibodies recognize microglia across different biological systems, including human AD tissue.
  • Evidence suggests a significant involvement of inflammation and immune mechanisms in AD pathogenesis.

Conclusions:

  • CSF microglial antibodies show promise as biomarkers for Alzheimer's disease.
  • Targeting microglial-driven inflammation represents a potential therapeutic avenue for AD.
  • Immune mechanisms are integral to the understanding and treatment of Alzheimer's disease.

More Related Videos

Immunofluorescence Staining Using IBA1 and TMEM119 for Microglial Density, Morphology and Peripheral Myeloid Cell Infiltration Analysis in Mouse Brain10:40

Immunofluorescence Staining Using IBA1 and TMEM119 for Microglial Density, Morphology and Peripheral Myeloid Cell Infiltration Analysis in Mouse Brain

Published on: October 27, 2019

Live Imaging and Characterization of Microglia Dynamics and Interactions with Synapses in Diseased Murine Retina07:19

Live Imaging and Characterization of Microglia Dynamics and Interactions with Synapses in Diseased Murine Retina

Published on: January 16, 2026

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...